Adriamycin, cisplatin, ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma. Analysis of three case reports and review of the literature

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 3041-3045

  Asmane, Irène ^a   Litique, Valère ^a   Heymann, Steve ^a   Marcellin, Luc ^a   Métivier, Anne Cécile ^a   Duclos, Brigitte ^a   Bergerat, Jean Pierre ^a   Kurtz, Jean Emmanuel ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Angiosarcoma; First line; Polychemotherapy

Indexed keywords

BLOOD CLOTTING FACTOR 8; CARBOPLATIN; CD31 ANTIGEN; CD34 ANTIGEN; CISPLATIN; DOXORUBICIN; ERYTHROPOIETIN; IFOSFAMIDE; PACLITAXEL; VIMENTIN;

ADULT; ADVANCED CANCER; AGED; ANAMNESIS; ANEMIA; ANGIOSARCOMA; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; MASTECTOMY; MEDICAL LITERATURE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOFT TISSUE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CISPLATIN; DOXORUBICIN; FEMALE; HEMANGIOSARCOMA; HUMANS; IFOSFAMIDE; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; PACLITAXEL; SOFT TISSUE NEOPLASMS; YOUNG ADULT;

EID: 55749107649     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Mark RJ, Poen JC, Tran LM, Fu YS and Juillard GF: Angiosarcoma. A report of 67 patients and a review of the literature. Cancer Jun 77(11): 2400-2406, 1996.
2. Cafiero F, Gipponi M, Peressini A, Queirolo P, Bertolglio S, Comandini D, Pierluigi P, Sertoli MR and Badellino F: Radiation-associated angiosarcoma. Diagnostic and therapeutic implications: two case reports and a review of the literature. Cancer 77: 2496-2502, 1996.
3. Klijanienko J, Caillaud JM, Lagace R and Viehl P: Cytohistologic correlations in angiosarcoma including classic and epithelioid variants. Diagn Cytopathol 29: 140-145, 2003.
4. Meis-Kindblom JM and Kindblom LG: Angiosarcoma of soft tissue: a study of 80 cases. Am J Surg Pathol Jun 22(6): 683-697, 1998.
5. Driemel O, Berndt A, Hartmann A, Mueller-Richter UD, Bauer R, Reichert TE and Kosmehi H: Clinical and immunohistochemical findings of intra- and extraoral angiosarcomas. Mund Kiefer Gesichtschir Jul 10(4): 239-247, 2006.
6. Loehrer PJ Sr, Sledge GW Jr, Nicaise C, Usakewicz J, Hainsworth JD, Martelo OJ, Omura G and Braun TJ: Ifosfamide plus doxorubicin in metastatic adult sarcomas: A multi-institutional phase II trial. J Clin Oncol 11: 1655-1659, 1990.
7. Schütte J, Mouridsen H, Stewart W, Santoro A, Van Oosteron AT, Somers R, Blackledge G, Verweij J, Dombernowsky P, Thomas D and Sylvester R: Ifosfamide plus adriamycin in previously untreated patients with advanced soft-tissue sarcomas: Final results of a phase II trial of the EORTC-STBSG. Eur J Cancer 26: 558-561, 1990.
8. Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E, Van Oosterom AT, Warwick J, Greifenberg B, Thomas D and Van Glabbeke M: Granulocyte macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft-tissue sarcomas: A study of the EORT-STBSG. J Clin Oncol 11: 15-21, 1993.
9. Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ and Van Hoesel Q: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte macrophage colony-stimulating factor in advanced soft-tissue sarcomas: a trial of the EORTC-STBSG. J Clin Oncol 18: 2676-2684, 2000.
10. Mathew P, Vakar-Lopez F and Trocoso P: Protracted remission of metastatic epithelioid angiosarcoma with weekly infusion of doxorubicin, paclitaxel, and cisplatin. Lancet Oncol 7(1): 92-93, 2006.
11. Eiling S, Lischner S, Busch J-O, Rothaupt D, Christophers E and Hauschild A: Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. British J Derm 147: 150-153, 2002.
12. Verdier E, Carvalo P, Young P, Musette P, Courville P and Joly P: Lymphangiosarcoma treated with liposomal doxorubicin. Ann Dermatol Venerol 134: 760-763, 2007.
13. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R and Taraboletti G: The microtubule-affecting drug paclitaxel has anti-angiogenic activity. Clin Cancer Res 2: 1843-49, 1996.
14. Bocci G, Nicolaou KC and Kerbel RS: Protracted low-dose effects on human endothelial cellproliferation and survival in vitro reveal a selective anti-angiogenic window for various chemotherapeutic drugs. Cancer Res 62: 6938-6943, 2002.
15. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B and O'Reilly MS: Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2000.
16. Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D and Kelsen DP: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86: 2034-2037, 1999.
17. Skubitz M and Haddad PA: Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 15: 361-366, 2005.